Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Respiratory Host-Pathogen Interaction

Project description

The role of virus-host interplay in immune response

Very few antiviral drugs have been approved for treating lower respiratory tract infections caused by influenza virus, respiratory syncytial virus and SARS-CoV-2. This paucity underscores the need for a better understanding of host-virus interaction during infection, to identify novel therapeutic targets. To address this unmet need, the EU-funded REACT project will investigate cellular, humoral and innate immunity during infection from these viruses. Using machine learning, researchers will analyse data from different ethnicities and disease severity and provide fundamental insight into immune response dynamics. Results on the identified factors critical for viral control and immune protection will be made widely available to aid the design of novel and personalised treatments against respiratory viruses.

Objective

Lower respiratory tract infections resulting from seasonal epidemics and pandemics are among the leading causes of death globally. There is a paucity of treatment options for viral respiratory pathogens and patient care remains largely supportive. This underscores a desperate need for identifying novel targets for prophylactic/treatment interventions and early prediction models of disease outcome to personalise treatment. The REACT consortium ? uniting high-level experts in virology, immunology, clinical medicine, epidemiology, and bioinformatics ? will assess genotypic, high-dimensional immunophenotypic, demographic and clinical data in the context of disease course to define host-pathogen interactions of viral respiratory tract infections, focusing on the predominating viruses i.e. influenza, respiratory syncytial virus (RSV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In characterised, ethnically diverse clinical cohorts comprising patients with varying disease severities, we will genotype both virus and host, map deep immunological phenotypes spanning cellular, humoral and innate immunity, and characterise host responses in human nasal epithelial organoid models following viral infection. Novel bioinformatics approaches that include knowledge discovery and machine learning will be used to integrate and analyse multidisciplinary datasets to assess the individual and combined impact of factors on disease phenotype. Information on the deep characterisation of the dynamics of the immune responses to the chosen viruses and identified factors critical for viral control and immune protection will be made available on a dedicated project website to clinicians, researchers, health authorities, and public. This will provide direct and immediate access to our findings for further development of personalised treatment, therapeutic targets and vaccines in future trials and clinical practice to improve the wellbeing of the EU population and beyond.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-RIA - HORIZON Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-HLTH-2021-DISEASE-04

See all projects funded under this call

Coordinator

STATENS SERUM INSTITUT
Net EU contribution
€ 1 220 000,00
Address
ARTILLERIVEJ 5
2300 Kobenhavn S
Denmark
Region
Danmark Hovedstaden Byen København
Activity type
Research Organisations
Links
Total cost
€ 1 220 000,00

Participants (10)